| Cash Flow | 2026-03-31 | 2025-12-31 |
|---|---|---|
| Net loss | -2,544 | -8,985 |
| Stock-based compensation | 467 | 4,725 |
| Prepaid expenses and other current assets | 395 | - |
| Accounts payable | 380 | 398 |
| Due to related party | 7 | -39 |
| Accrued expenses related party | 22 | 23 |
| Accrued expenses and other current liabilities | - | -66 |
| Net cash flows used in operating activities | -2,063 | -3,944 |
| Payments related to issuance of common stock | - | 27 |
| Proceeds from issuance of common stock | - | 4,493 |
| Net cash flows provided by financing activities | - | 4,466 |
| Net decrease in cash and cash equivalents | -2,063 | 522 |
| Cash and cash equivalents, beginning | 5,143 | 4,621 |
| Cash and cash equivalents, ending | 3,080 | 5,143 |
Polaryx Therapeutics, Inc. (PLYX)
Polaryx Therapeutics, Inc. (PLYX)